Cardlytics

Cardlytics, Inc. engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded by Scott D. Grimes, Lynne M. Laube, and Hans Theisen on June 26, 2008 and is headquartered in Atlanta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cardlytics reports robust Q4 performance and eyes positive cash flow

Cardlytics delivered a strong performance in Q4 2022, marked by robust financial results and operational improvements.
The company's strategic focus on cost management, product enhancements, and consumer engagement bodes well for future growth.
While facing challenges in a competitive landscape, Cardlytics is poised to capitalize on opportunities through innovation and strategic initiatives.
Guidance for Q1 2023 and the target for positive free cash flow in Q3 2023 reflect a positive outlook for the company's financial health.

Cardlytics (CDLX) surpasses Q1 expectations amidst cautious advertiser sentiment

Cardlytics (CDLX) reported strong Q1 2023 earnings, exceeding expectations with growth in unique consumers activating offers and improved cost discipline.
The company faces challenges from cautious advertisers and client concentration risks, requiring strategic management and diversification efforts.
Opportunities for growth include expanding the partner network, driving user engagement, and innovating in product offerings to maintain competitiveness.

Cardlytics reports mixed Q2 results, eyes partnerships for growth

Cardlytics navigated mixed financial results in Q2 2023, focusing on cost optimizations and strategic initiatives. The company aims for positive annual adjusted EBITDA and operating cash flow in 2024 amidst market variability and economic uncertainty.

Cardlytics reports positive Q3 results, eyes global expansion and new products

Cardlytics delivered positive Q3 results, showcasing growth in revenue, partnerships, and strategic initiatives. Challenges include revenue factors and product adoption, while opportunities exist in new product offerings and global expansion. The company remains optimistic about future prospects and business success.

Cardlytics reports record Q4 earnings, eyes growth through redemptions

Cardlytics achieved a milestone with its first positive annual adjusted EBITDA since 2019 and recorded its largest adjusted EBITDA in Q4. The company is strategically positioned for growth with new partnerships, product launches, and a focus on driving redemptions. Challenges lie in maintaining financial performance and capital structure.

Cardlytics (CDLX) posts robust Q1 results, eyes growth opportunities

Cardlytics (CDLX) reported strong Q1 2024 results with notable billings and revenue growth, positive adjusted EBITDA, and progress in strategic initiatives. While facing challenges in Q2 projections and analyst inquiries, the company remains focused on capitalizing on growth opportunities and market trends.

Cardlytics reports mixed Q2 results, focuses on growth opportunities

Cardlytics shows resilience with positive adjusted EBITDA in 2023 and improved financial stability
Despite missing Q2 guidance, the company is addressing delivery issues and focusing on growth areas
Strong relationships with financial institutions and plans for business evolution under new leadership
Q3 outlook includes challenges but also opportunities for expansion and performance acceleration

Cardlytics faces Q3 revenue decline, eyes growth through strategic investments

Cardlytics navigated Q3 challenges with a focus on enhancing key aspects of its business. The company's strategic priorities include supply, demand, network performance, and investments in growth initiatives like Bridg and Rippl.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardlytics, Inc. engages in the business of operating an advertising platform which includes online, mobile applications, email, and various real-time notifications. It operates under the Cardlytics and Bridg Platforms. The Cardlytics Platform segment focuses on the United States and the United Kingdom, which represents proprietary advertising channels. The Bridg Platform segment is involved in utilizing POS data from merchant data partners, including product-level purchase data to enable marketers to perform analytics and targeted loyalty marketing in a privacy protected manner. The company was founded by Scott David Grimes, Lynne Marie Laube, and Hans Theisen on June 26, 2008 and is headquartered in Atlanta, GA.

Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Cardlytics (CDLX)

Cardlytics, Inc. (CDLX) Q3 2024 Earnings Call Transcript

Cardlytics (CDLX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.01 per share a year ago.

Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates

ATLANTA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the third quarter ended September 30, 2024.

Cardlytics Announces Third Quarter 2024 Financial Results

ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks' digital channels, today announced that its financial results for the third quarter ending September 30, 2024 will be released on November 6, 2024, after market close. The results will be discussed via conference call at 5:00 PM ET / 2:00 PM PT.

Cardlytics Announces Timing of Its Third Quarter 2024 Earnings Release

NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ: CDLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX

SAN FRANCISCO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Cardlytics (CDLX) Under Investor Scrutiny About Growth Initiatives – Hagens Berman

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Cardlytics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cardlytics (CDLX)

NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Cardlytics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - CDLX

LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cardlytics Inc May Have Defrauded Investors And Impacted Individuals Can Join The Schall Law Firm's Inquiry

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

CDLX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Cardlytics, Inc. investment

Shareholders that Lost Money on Cardlytics, Inc.(CDLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - CDLX

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Cardlytics, Inc. Violated Securities Regulations And Shareholders Are Urged To Reach Out

NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Shareholders that Lost Money on Cardlytics, Inc. (CDLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - CDLX

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cardlytics Inc May Have Defrauded Investors And Those With Losses Should Join The Schall Law Firm's Inquiry

NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

An Investigation Has Commenced on Behalf of Cardlytics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CDLX Losses.

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Cardlytics, Inc. Committed Securities Law Violations And Stockholders Are Invited To Take Part

Levi & Korsinsky Reminds Shareholders of an Investigation into Cardlytics, Inc. (CDLX) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Levi & Korsinsky Reminds Cardlytics Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CDLX

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cardlytics Inc May Have Defrauded Investors And Those With Losses Should Contact The Schall Law Firm About An Investigation

NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

ATTENTION CDLX SHAREHOLDERS: Investors Who Lost Money on Cardlytics, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses In Cardlytics Inc Are Encouraged To Contact The Schall Law Firm About An Investigation Into Possible Securities Fraud

NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Cardlytics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - CDLX

Cardlytics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- CDLX

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Cardlytics Stock (CDLX)